Ipratropium Adultes Aguettant

Ipratropium Bromide, the active ingredient in Ipratropium Adultes Aguettant, is an anticholinergic (muscarinic antagonist) presented as an inhalation solution for inhalation use. It provides bronchodilation for adults with chronic obstructive pulmonary disease (COPD) and asthma.

GNH USA supplies Ipratropium Adultes Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium Bromide is used to manage airway obstruction in chronic respiratory diseases.

- Chronic obstructive pulmonary disease (COPD): improves airflow and reduces exacerbations. - Asthma: provides bronchodilation as an add‑on maintenance therapy. - Bronchospasm: relieves acute bronchospasm associated with COPD or asthma.

Common Side Effects: - Dry mouth: reduced salivary secretion. - Cough: irritation of the airway. - Throat irritation: mild soreness after inhalation. - Headache: transient discomfort. - Dizziness: occasional light‑headedness. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Angioedema: swelling of lips, tongue or face. - Severe allergic reaction: rash, hives, or anaphylaxis. - Tachycardia: rapid heart rate. - Urinary retention: difficulty emptying the bladder. - Vision changes: blurred vision or increased intra‑ocular pressure.

Before initiating therapy, evaluate the patient's respiratory diagnosis and assess for contraindications.

- Assess respiratory status: confirm COPD or asthma diagnosis before use. - Monitor anticholinergic effects: watch for dry mouth, urinary retention, or glaucoma exacerbation. - Avoid in patients with hypersensitivity to ipratropium or atropine derivatives. - Use with caution in narrow‑angle glaucoma or prostatic hypertrophy. - Store at room temperature: keep in original container, protect from moisture and heat.

Ipratropium may interact with other medications that affect the cholinergic system or bronchodilation.

Major Interactions (Avoid): - Concurrent use with other muscarinic antagonists (e.g., tiotropium): risk of additive anticholinergic effects. - Co‑administration with cholinesterase inhibitors (e.g., pyridostigmine): may reduce therapeutic benefit.

Moderate Interactions (Monitor Closely):\n- Beta‑agonists (e.g., albuterol): monitor for additive bronchodilation and tremor. - Theophylline: observe for altered plasma levels. - Inhaled corticosteroids: increased risk of oral thrush; advise proper mouth rinsing.